Eruptive Junctional Nevi Appearing During Langerhans Cell Histiocytosis Treatment

  • Maria Mendonça-Sanches Dermatology Department, Hospital de Santa Maria, Lisbon, Portugal
  • Ines Rolim Pathology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
  • Joaninha Costa-Rosa Pathology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
  • Gabriela Caldas Pediatrics Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
  • Cecilia Moura Dermatology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Keywords

Langerhans cell histiocytosis, eruptive nevi, chemotherapy, neoplastic disorder

Abstract

Langerhans cell histiocytosis (LCH) is a multisystemic disorder that results from the clonal proliferation of immunophenotypically and functionally immature Langerhans cells (LC). The detection of the V600E mutation in the BRAF oncogene in LCH biopsy specimens supports previous evidence that LCH is a neoplastic disorder. This mutation is present in other cutaneous lesions including malignant melanoma and benign nevi. Single case reports of a correlation between LCH and the appearance of eruptive nevi limited to the inguinal folds after chemotherapy have previously been described in the literature. This suggested that LCH could be an additional cause of eruptive melanocytic nevi, with a specific distribution mimicking that of LCH cutaneous lesions. We present the case of a 6-year-old boy, previously treated with chemotherapy for Langerhans cell histiocytosis, with disseminated junctional nevi. Although this co-occurrence may be coincidental, the skin involvement is distinct from other previously reported clinical cases. It would be interesting to evaluate whether the BRAF mutation described in LCH cells might in fact support a genetic background for the development of nevi in these patients.

References

  • Laman JD, Leenen PJ, Annels NE, et al. Langerhans-cell histiocytosis 'insight into DC biology'. Trends Immunol 2003;24(4):190–196.

  • Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med 1994;331(3):154–160.

  • Tillotson C, Bhimji S. Histiocytosis, Langerhans Cell. Treasure Island, FL: StatPearls Publishing; 2017.

  • Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 1994;343(8900):767–768.

  • Dimmler A, Geddert H, Werner M, et al. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. Virchows Arch 2017;470(4):429–435.

  • Badalian-Very G, Vergilio JA, Fleming M, et al. Pathogenesis of Langerhans cell histiocytosis. Annu Rev Pathol 2013;8:1–20.

  • Braier JL, Rosso D, Latella A, et al. Importance of multi-lineage hematologic involvement and hypoalbuminemia at diagnosis in patients with "risk-organ" multi-system Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2010;32(4):e122–e125.

  • Héritier S, Jehanne M, Leverger G, et al. Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis. JAMA Oncol 2015;1(6):836–838.

  • Berk DR, Lane AT. Acquired bilateral agminated Spitz nevi in a child with Langerhans cell histiocytosis. Pediatr Dermatol 2010;27(3):282–284.

  • Surinach C, Bahadoran P, Vabres P, et al. Flexural agminated eruptive nevi in Langerhans cell histiocytosis. JAMA Dermatol 2013;149(5):635–637.

  • Senechal B, Elain G, Jeziorski E, et al. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med 2007;4(8):e253.

  • Egeler RM, Favara BE, van Meurs M, et al. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 1999;94(12):4195–4201.

  • Funasaka Y, Chakraborty AK, Hayashi Y, et al. Modulation of melanocyte stimulating hormone receptor expression on normal human melanocytes: evidence for a regulatory role of ultraviolet B, interleukin-1alpha, interleukin-1beta, endothelin-1 and tumour necrosis factor-alpha. Br J Dermatol 1998;139(2):216–224.

  • Cardones AR, Grichnik JM. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol 2009;145(4):441–444.
  • Published: 2019-06-05

    Issue: Vol 6 No 6 (view)

    Section: Articles

    How to cite:
    Mendonça-Sanches, M., Rolim, I., Costa-Rosa, J., Caldas, G., & Moura, C. (2019). Eruptive Junctional Nevi Appearing During Langerhans Cell Histiocytosis Treatment. European Journal of Case Reports in Internal Medicine, 6(6). https://doi.org/https://doi.org/10.12890/2019_001088

    Most read articles by the same author(s)